Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 3/2013

01-06-2013 | Urology - Original Paper

Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature

Authors: C. E. Gzell, J. G. Kench, M. R. Stockler, G. Hruby

Published in: International Urology and Nephrology | Issue 3/2013

Login to get access

Abstract

Aims

Prostate cancer is very common and is the second most common cause of cancer death in males in Australia; however, brain metastases are exceedingly rare.

Materials and methods

We review four cases of biopsy-proven brain metastases from prostate cancer and review the relevant literature.

Results

Three of four patients had acinar adenocarcinoma of prostate with one patient having ductal adenocarcinoma variant on histopathology. Three patients had the brain as the only site of metastatic disease. All patients underwent surgery, and three of four patients underwent adjuvant palliative radiotherapy to the brain.

Conclusion

Brain metastases from prostate cancer are rare, but brain metastases without other sites of metastatic disease are exceedingly rare and may be more common with ductal adenocarcinoma variant.
Literature
1.
Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK (2003) Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer 98(2):363–368PubMedCrossRef
2.
Catane R, Kaufman J, West C, Merrin C, Tsukada Y, Murphy GP (1976) Brain metastasis from prostatic carcinoma. Cancer 38(6):2583–2587PubMedCrossRef
3.
Demierre B, Berney J (1983) Intracranial metastases of cancer of the prostate. Neurochirurgie 29(2):143–149PubMed
4.
Taylor HG, Lefkowitz M, Skoog SJ, Miles BJ, McLeod DG, Coggin JT (1984) Intracranial metastases in prostate cancer. Cancer 53(12):2728–2730PubMedCrossRef
5.
Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T (1984) Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 54(12):3078–3084PubMedCrossRef
6.
Behrens B, Husain MM, Schmidley JW (2001) Cystic solitary intracerebral metastasis from prostate adenocarcinoma. Neuroradiology 43(2):162–164PubMedCrossRef
7.
Lynes WL, Bostwick DG, Freiha FS, Stamey TA (1986) Parenchymal brain metastases from adenocarcinoma of prostate. Urology 28(4):280–287PubMedCrossRef
8.
Castro Gómez JE, Anido Herranz U, Carballo Castro A, Gómez Caamaóo A, León Mateos LA, Porto Vázquez C et al (2009) Brain metastases from prostate adenocarcinoma. Clin Transl Oncol 11(1):63–64PubMedCrossRef
9.
Gupta A, Baidas S, Cumberlin RK (1994) Brain stem metastasis as the only site of spread in prostate carcinoma. A case report. Cancer 74(9):2516–2519PubMedCrossRef
10.
Hayashi T, Igarashi K, Tanizawa A, Terada Y, Sekine H (1998) Brain metastasis as a sole recurrence of prostate cancer after total prostatectomy. Urol Int 60(2):121–123PubMedCrossRef
11.
Roberts-Thomson R, Rosenthal MA, Gonzales M, Drummond K (2009) Brain metastases in hormone refractory prostate cancer: a changing natural history? Intern Med J 39(3):205–206PubMedCrossRef
12.
Salvati M, Frati A, Russo N, Brogna C, Piccirilli M, D’Andrea G et al (2005) Brain metastasis from prostate cancer. Report of 13 cases and critical analysis of the literature. J Exp Clin Cancer Res 24(2):203–207PubMed
13.
Humphrey PA (2012) Histological variants of prostatic carcinoma and their significance. Histopathology 60(1):59–74PubMedCrossRef
14.
Eade TN, Al-Saleem T, Horwitz EM, Buyyounouski MK, Chen DYT, Pollack A (2007) Role of radiotherapy in ductal (Endometrioid) carcinoma of the prostate. Cancer 109(10):2011–2015PubMedCrossRef
15.
Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL (2010) Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol 184(6):2303–2307PubMedCrossRef
16.
Orihuela E, Green JM (2008) Ductal prostate cancer: contemporary management and outcomes. Urol Oncol 26(4):368–371PubMedCrossRef
17.
McCutcheon IE, Eng DY, Logothetis CJ (1999) Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer 86(11):2301–2311PubMedCrossRef
18.
Grenader T, Shavit L, Lossos A, Pizov G, Wygoda M (2007) Brain metastases: a rare initial presentation of prostate cancer. Int Urol Nephrol 39(2):537–539PubMedCrossRef
19.
Chitale S, Webb R, MacIver D, Peat D (2008) Multifocal symptomatic intracerebral metastases as the first manifestation of prostatic carcinoma: a report and literature review. Int Urol Nephrol 40(3):675–678PubMedCrossRef
20.
Kim S-H, Chao ST, Toms SA, Vogelbaum MA, Barnett GH, Suh JH et al (2008) Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma. Surg Neurol 69(6):641–646 (discussion 646)
21.
Flannery T, Kano H, Niranjan A, Monaco EA 3rd, Flickinger JC, Lunsford LD et al (2010) Stereotactic radiosurgery as a therapeutic strategy for intracranial metastatic prostate carcinoma. J Neurooncol 96(3):369–374PubMedCrossRef
22.
Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MVP, Van Bokhoven A et al (2011) Development of a brain metastatic canine prostate cancer cell line. Prostate 71(12):1251–1263PubMed
Metadata
Title
Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature
Authors
C. E. Gzell
J. G. Kench
M. R. Stockler
G. Hruby
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-013-0462-7

Other articles of this Issue 3/2013

International Urology and Nephrology 3/2013 Go to the issue

Nephrology - Letter to the Editor

Sturge–Weber syndrome coexisting with autosomal dominant polycystic kidney disease

Nephrology – Letter to the Editor

First hospitalization after kidney transplantation

Urology – Review

Non-obstructive azoospermia and clinical varicocele: therapeutic options

Urology - Original Paper

Diagnostic performance of initial transperineal 14-core prostate biopsy to detect significant cancer

Nephrology - Original Paper

Smad7 inhibits TGF-β1-induced MCP-1 upregulation through a MAPK/p38 pathway in rat peritoneal mesothelial cells

Urology - Original Paper

Bilateral synchronous sporadic renal masses: intermediate functional and oncological outcomes at a single institution
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits